Protective capacity of the human anamnestic antibody response during acute dengue virus infection

Journal of Virology

Volumn 90, Issue 24, 2016, Pages 11122-11131

  Xu, Meihui ^a   Züst, Roland ^a,d   Toh, Ying Xiu ^a   Pfaff, Jennifer M ^b   Kahle, Kristen M ^b   Davidson, Edgar ^b   Doranz, Benjamin J ^b   Velumani, Sumathy ^a   Tukijan, Farhana ^a,c   Wang, Cheng I ^a   Fink, Katja ^a,c  

^a AGENCY FOR SCIENCE   (Singapore)

^b Integral Molecular Inc   (United States)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d SPIEZ LABORATORY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

E PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; E PROTEIN TH SMAN, DENGUE VIRUS; NEUTRALIZING ANTIBODY; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE; ENDOSOME; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PH; PLASMABLAST; PRIORITY JOURNAL; PROTECTION; PROTEIN DOMAIN; SECONDARY INFECTION; SEROTYPE; VIREMIA; VIRUS NEUTRALIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; CLASSIFICATION; DENGUE VIRUS; DISEASE MODEL; DRUG EFFECTS; EPITOPE MAPPING; GENE EXPRESSION; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PROTEIN STABILITY; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES; GENE EXPRESSION; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; MICE; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN STABILITY; VIRAL ENVELOPE PROTEINS;

EID: 85000961951     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01096-16     Document Type: Article

References (41)

1. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010 Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748. http://dx.doi.org/10.1126/science.1185181.
2. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. http://dx.doi.org/10.1038/ni.3058.
3. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. http://dx.doi.org/10.1016/j.chom.2010.08.007.
4. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brian J, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. http://dx.doi.org/10.1371/journal.pntd.0001188.
5. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012 Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad SciUS A 109:7439-7444. http://dx.doi.org/10.1073/pnas.1200566109.
6. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE, Jr. 2014 Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol 88: 12233-12241. http://dx.doi.org/10.1128/JVI.00247-14.
7. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, Ong SH, Warter L, Leo YS, Wang CI, Fink K. 2012. Plasmablasts generated during repeated dengue infection are virus glycoproteinspecific and bind to multiple virus serotypes. J Immunol 189:5877-5885. http://dx.doi.org/10.4049/jimmunol.1201688.
8. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Hj Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, CYD-TDV Dengue Vaccine Working Group. 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195-1206. http://dx.doi.org/10.1056/NEJMoa1506223.
9. Rothman AL. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11:532-543. http://dx.doi.org/10.1038/nri3014.
10. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, Macary PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139ra83. http://dx.doi.org/10.1126/scitranslmed.3003888.
11. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Jr, Lok SM. 2014 A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6:358-371. http://dx.doi.org/10.1002/emmm.201303404.
12. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725. http://dx.doi.org /10.1016/S0092-8674(02)00660-8.
13. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type-and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816-12826. http://dx.doi.org/10.1128 /JVI.00432-07.
14. Wahala WM, Huang C, Butrapet S, White L, de Silva AM. 2012. Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86: 4019-4023. http://dx.doi.org/10.1128/JVI.06871-11.
15. Zhou Y, Austin SK, Fremont DH, Yount BL, Huynh JP, de Silva AM, Baric RS, Messer WB. 2013. The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology 439: 57-64. http://dx.doi.org/10.1016/j.virol.2013.01.022.
16. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319 http://dx.doi.org/10.1038/nature02165.
17. Velumani S, Toh YX, Balasingam S, Archuleta S, Leo YS, Gan VC, Thein TL, Wilder-Smith A, Fink K. 2016. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees. Hum Vaccin Immunother 12:1265-1273. http://dx.doi.org/10.1080/21645515.2015.1126012.
18. Umashankar M, Sanchez-San Martin C, Liao M, Reilly B, Guo A, Taylor G, Kielian M. 2008. Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol 82:9245-9253 http://dx.doi.org/10.1128/JVI.00975-08.
19. Davidson E, Doranz BJ. 2014. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 143:13-20. http://dx.doi.org/10.1111/imm.12323.
20. Ito M, Katakai Y, Ono F, Akari H, Mukai RZ, Takasaki T, Kotaki A, Kurane I. 2011. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes. Arch Virol 156:1073-1077. http://dx.doi.org/10.1007 /s00705-011-0959-2.
21. Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE. 1985. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg 34:162-169.
22. Crill WD, Chang GJ. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78:13975-13986. http://dx.doi.org/10.1128/JVI.78.24.13975-13986.2004.
23. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:9557-9568. http://dx.doi.org/10.1128/JVI.00080-06.
24. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631-6643. http://dx.doi.org/10.1128/JVI.00316-08.
25. Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK. 2013. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 7:e2451. http://dx.doi.org/10.1371/journal.pntd.0002451.
26. Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, Paes C, Davidson E, Doranz BJ. 2013. Atomic-level functional model of dengue virus Envelope protein infectivity. Proc Natl Acad Sci U S A 110: 18662-18667. http://dx.doi.org/10.1073/pnas.1310962110.
27. Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE, Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS. 2016. Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1. J Virol 90:5090-5097. http://dx.doi.org/10.1128/JVI.00155-16.
28. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE, Jr. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4:e00873-00813. http://dx.doi.org/10.1128/mBio.00873-13.
29. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Despres P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109-113. http://dx.doi.org/10.1038 /nature14130.
30. Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. 2014. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol 88:7210-7220. http: //dx.doi.org/10.1128/JVI.03690-13.
31. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. 2010. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 4:e672. http://dx.doi.org/10.1371/journal.pntd.0000672.
32. Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y, Chokephaibulkit K, Angkasekwinai N, Pattanapanyasat K, Ahmed R, Wilson PC, Wrammert J. 2016. B cell responses during secondary dengue infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol 90:5574-5585. http://dx.doi.org/10.1128/JVI.03203-15.
33. Singla M, Kar M, Sethi T, Kabra SK, Lodha R, Chandele A, Medigeshi GR. 2016. Immune response to dengue virus infection in pediatric patients in New Delhi, India; association of viremia, inflammatory mediators and monocytes with disease severity. PLoS Negl Trop Dis 10: e0004497. http://dx.doi.org/10.1371/journal.pntd.0004497.
34. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. 2011. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl Trop Dis 5:e1309. http://dx.doi.org/10.1371/journal.pntd.0001309.
35. Duyen HT, Ngoc TV, Ha DT, Hang VT, Kieu NT, Young PR, Farrar JJ, Simmons CP, Wolbers M, Wills BA. 2011. Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J Infect Dis 203:1292-1300 http://dx.doi.org/10.1093/infdis/jir014.
36. Zust R, Toh YX, Valdes I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillen G, Kalinke U, Shi PY, Fink K. 2014. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J Virol 88:7276-7285 http://dx.doi.org/10.1128/JVI.03827-13.
37. Duhan V, Khairnar V, Friedrich SK, Zhou F, Gassa A, Honke N, Shaabani N, Gailus N, Botezatu L, Khandanpour C, Dittmer U, Haussinger D, Recher M, Hardt C, Lang PA, Lang KS. 2016. Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8(+) T-cell priming and viral control. Sci Rep 6:19191. http://dx.doi.org/10.1038/srep19191.
38. Honke N, Shaabani N, Cadeddu G, Sorg UR, Zhang DE, Trilling M, Klingel K, Sauter M, Kandolf R, Gailus N, van Rooijen N, Burkart C, Baldus SE, Grusdat M, Lohning M, Hengel H, Pfeffer K, Tanaka M, Haussinger D, Recher M, Lang PA, Lang KS. 2012. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 13:51-57. http://dx.doi.org/10.1038/ni.2169.
39. Kostyuchenko VA, Lim EX, Zhang S, Fibriansah G, Ng TS, Ooi JS, Shi J, Lok SM. 2016. Structure of the thermally stable Zika virus. Nature 533:425-428. http://dx.doi.org/10.1038/nature17994.
40. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog 7:e1002111. http://dx.doi.org/10.1371/journal.ppat.1002111.
41. Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, Fremont DH. 2009. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 5:e1000453. http://dx.doi.org/10.1371/journal.ppat.1000453.